 Home > Active Ingredient News > Antitumor Therapy > Does shortening the duration of radiotherapy have an effect on the efficacy of patients with early-stage breast cancer who are at high risk of recurrence?

Does shortening the duration of radiotherapy have an effect on the efficacy of patients with early-stage breast cancer who are at high risk of recurrence?

 Last Update: 2022-11-15
 Source: Internet
 Author: User

Tags

prohormones side effects

streptococcus viridans group

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

*For medical professionals reading only

to see what was said at the ASTRO conference!

Executive summary

On October 24, 2022, a study at the annual meeting of the American Society of Radiation Oncology (ASTRO) showed that shortening the duration of radiation therapy did not affect the efficacy
of patients with early-stage breast cancer who are at high risk of recurrence.

Research screenshots

status quo

Previous studies have shown that a three-week course of radiation therapy is just as safe and effective as a traditional six-week course of radiation therapy for patients at low risk of tumor recurrence, but additional radiation therapy to the site of tumor resection is required
for patients at higher risk of tumor recurrence.

Frank a.
Vicini, MD, radiation oncologist, director of research at GenesisCare, principal investigator of FASTRO, said

Supplemental radiation therapy can reduce the likelihood of breast tumour recurrence by 20% to 30%, but adding this increased dose of radiotherapy after hypofractionated radiotherapy increases the duration
of treatment by one week.
This is a challenge
for patients who need to take time off or travel long distances for treatment.
The trial wanted to investigate whether this increased dose of radiotherapy could be equally effective in delivering efficacy while shortening the treatment process, without increasing side effects or affecting breast appearance
.

conclusion

Participants in the trial included 2262 patients
with early-stage breast cancer who were at high risk of local recurrence after lumpectomy.
Risk factors include tumor grade, age, whether to receive preoperative chemotherapy and estrogen receptor status
.
The median age of the patients was 55 years, and patients were treated
at 276 different sites in the United States, Canada, Switzerland, Israel, Hong Kong, Japan, South Korea and Singapore.

In this study, patients were randomly divided into two study groups
.
Group A patients (n=1124) received routine total breast radiation therapy for 4 to 5 weeks, followed by continuous increased treatment
at the tumor resection site within 6 to 7 days.
Group B patients (n=1138) received hypofractionated whole-breast radiotherapy for three weeks, while the surgical site was given increased radiotherapy
during these three weeks.

At a median follow-up of 7.
3 years, there were 56 cases of intramammary recurrence
among nearly 2300 study participants.
Regarding breast tumor recurrence, the primary endpoint of the study, group B was no lower than group A (HR: 1.
32, 90% CI: 0.
84 to 2.
05, p=0.
039).

The 5-year and 7-year recurrence rates were 1.
9% and 2.
6% in group B, and 2.
0% and 2.
2%
in group A, respectively.

There were also no significant differences
between the two groups in terms of appearance or side effects.
At 3 years after treatment, 86% and 84% of patients in groups A and B, respectively, had their appearance rated as excellent or good
by their doctors.
Severe (grade ≥ 3) side effects were uncommon in both groups, 3.
3% in group A and 3.
5%
in group B.

prospect

Frank a.
Vicini, MD, radiation oncologist, director of research at GenesisCare, principal investigator of FASTRO, said:

This approach cuts the treatment time of these patients in half and is suitable for patients at
high risk of recurrence.
In-depth knowledge of breast cancer therapies and advances in treatment techniques may be behind
the low recurrence rates and side effects.
Over the years, surgery, pathology reports, radiotherapy, chemotherapy – these things have been constantly improving
.
We can administer it
in a more complex way.
As a result, the recurrence rate is decreasing, while the success rate of treatment is rising
.
”

The next questions the team needs to answer include whether more patients could benefit from the three-week treatment, such as those whose cancer has spread to lymph nodes, and whether treatment time can be shortened
further.
For example, a study in the United Kingdom is giving a week of radiotherapy
to patients at low risk of recurrence.

Commentary first published: Medical press

Written by the American Society for Radiation Oncology

Click "Read Original" to get more clinical dry goods

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.